Q1 sales revenue ends at NOK 16.2m (up 15% from Q4/19)
fCAL continues the strong growth, Covid-19 might affect Q2
Cystatin C performs well as the kidney marker is unaffected by COVID-19
Launch of GCAL and fPELA could secure higher growth in H2/20 + H1/21
24 Apr 2020
Q1- growth in revenue – low COVID-19 impact
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1- growth in revenue – low COVID-19 impact
Q1 sales revenue ends at NOK 16.2m (up 15% from Q4/19)
fCAL continues the strong growth, Covid-19 might affect Q2
Cystatin C performs well as the kidney marker is unaffected by COVID-19
Launch of GCAL and fPELA could secure higher growth in H2/20 + H1/21